期刊
NANOMATERIALS
卷 9, 期 4, 页码 -出版社
MDPI
DOI: 10.3390/nano9040638
关键词
lipid-based nanoparticles; cancer; drug release; drug resistance; clinical trials
类别
资金
- Consejeria de Salud de la Junta de Andalucia [PI-0476-2016, PI-0102-2017]
- CICYT, Spain [CTQ16-76311]
- Ministerio Ciencia, Innovacion y Universidades [FPU16/01716]
Many therapeutically active molecules are non-soluble in aqueous systems, chemically and biologically fragile or present severe side effects. Lipid-based nanoparticle (LBNP) systems represent one of the most promising colloidal carriers for bioactive organic molecules. Their current application in oncology has revolutionized cancer treatment by improving the antitumor activity of several chemotherapeutic agents. LBNPs advantages include high temporal and thermal stability, high loading capacity, ease of preparation, low production costs, and large-scale industrial production since they can be prepared from natural sources. Moreover, the association of chemotherapeutic agents with lipid nanoparticles reduces active therapeutic dose and toxicity, decreases drug resistance and increases drug levels in tumor tissue by decreasing them in healthy tissue. LBNPs have been extensively assayed in in vitro cancer therapy but also in vivo, with promising results in some clinical trials. This review summarizes the types of LBNPs that have been developed in recent years and the main results when applied in cancer treatment, including essential assays in patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据